Why the study?
Data on the prevalence and clinical consequences of hyperkalaemia in patients taking RAASi within a dedicated heart failure care setting are scarce.
In heart failure patients, hyperkalaemia frequently leads to MRA discontinuation, which is associated with increased mortality, highlighting the importance of maintaining MRA therapy when possible.
Answers are grounded in this paper and cite their sources.
Hyperkalaemia warrants monitoring to avoid RAASi underdosing in HF; leaves open whether prevention alters mortality or admissions.
Background Hyperkalaemia is a potentially life-threatening condition. Furthermore, it is one of the main reasons for discontinuation and dose reduction of renin-angiotensin-aldosterone system inhibitors (RAASi) in clinical practice. However, exact data on the prevalence and consequences of occurrence of hyperkalaemia when taking RAASi in a dedicated heart failure care setting are scarce.Methods Consecutive patients diagnosed with heart failure from a single tertiary hospital between August 2000 and May 2017 were retrospectively evaluated. Primary endpoint was the development of hyperkalaemia (≥5.5 mmol/L) at any moment during follow-up.Results About 396 patients were included in the current analysis (mean follow-up 6.9 years). 26% (n = 104) and 12% (n = 46) of patients developed hyperkalaemia (≥5.5 mmol/L and ≥6.0 mmol/L, respectively). Diabetes mellitus (OR = 1.80, 95% CI = 1.03–3.19) and baseline creatinine (mg/dL) (OR = 2.37, 95% CI = 2.37–3.85) were independent risk factors for hyperkalaemia. Development of hyperkalaemia was associated with 6.5 higher odds for recurrence. Only 10% developed hyperkalaemia during up-titration of RAASi, while 90% developed during later follow-up on stable doses of RAASi. hyperkalaemia was not associated with worse outcome after multivariate adjustment for baseline co-morbidities. However, hyperkalaemia was associated with discontinuation and lower doses of MRAs during follow-up (p = 0.007). Discontinuation of MRA due to hyperkalaemia was associated with an increase in all-cause mortality in HFrEF patients (HR = 1.77, 95% CI = 1.05–2.99).Conclusions Approximately, one-fourth of patients developed hyperkalaemia during follow-up which was associated with a lower MRA dose during follow-up. Discontinuation of MRA, but not hyperkalaemia itself, was associated with an increased risk of all-cause mortality and heart failure admission in HFrEF patients.
No takes yet. Share an insight, caveat, or question.
Martens et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: